EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aldeyra Therapeutics's Enterprise Value is $106.61 Mil.
Aldeyra Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-30.86 Mil. Therefore, Aldeyra Therapeutics's EV-to-FCF for today is -3.46.
The historical rank and industry rank for Aldeyra Therapeutics's EV-to-FCF or its related term are showing as below:
ALDX'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.39 Med: 0 Max: 1.05
Current: -3.46
During the past 13 years, the highest EV-to-FCF of Aldeyra Therapeutics was 1.05. The lowest was -8.39. And the median was 0.00.
ALDX's EV-to-FCF is ranked worse than 100% of 389
companies
in the Biotechnology industry
Industry Median: 6.49
vs ALDX: -3.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Aldeyra Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aldeyra Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Aldeyra Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's EV-to-FCF falls into.
Aldeyra Therapeutics's current Enterprise Value is $106.61 Mil.
Aldeyra Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aldeyra Therapeutics's PE Ratio for today is calculated as:
Aldeyra Therapeutics's share price for today is $3.70.
Aldeyra Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aldeyra Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Aldeyra Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALDX has been successfully added to your 